Therapeutic Challenges in the Use of Chemotherapy and Cyclin-Dependent Kinase 4/6 Inhibitors in a Patient With Charcot-Marie-Tooth Disease and Breast Cancer

We report a rare clinical scenario involving a 65-year-old female patient with Charcot-Marie-Tooth (CMT) disease who was diagnosed with early-stage breast carcinoma. The patient underwent neoadjuvant chemotherapy, followed by surgery and adjuvant endocrine therapy. During treatment, she developed grade 3 peripheral neuropathy, leading to the early discontinuation of paclitaxel and subsequent therapeutic adjustments. This report highlights the challenges of managing patients with neuromuscular comorbidities undergoing chemotherapy and the use of cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors as adjuvant therapy in breast cancer treatment.